GRF-6019 is under clinical development by Alkahest and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GRF-6019’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GRF-6019 overview
GRF-6019 is under development for the treatment of mild to moderate and advanced Alzheimer's disease and Parkinson's disease. The drug candidate is a plasma protein fraction. It is administered through intravenous route.
Alkahest overview
Alkahest, is a subsidiary of Grifols, S.A., is a clinical stage biopharmaceutical company. It’s pipeline products include AKST4290, GRF6019/6021 and AKST1210. Alkahest is involved in treatment of developing transformative therapies for aging plasma proteome, neurodegenerative and age-related diseases. The company is an orally administered inhibitor against CCR3, GRF6019 and GRF6021 are human plasma fractions used for the treatment of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. Alkahest is headquartered in San Carlos, California, the US.
For a complete picture of GRF-6019’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
